Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Goli Samimi

Showing results (41-50 of 73) with videos related to

Pageof 8
Sort By:
Cancer Chemotherapy and Pharmacology|September 21, 2004
cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistanceGoli Samimi, Gerald Manorek, Rob Castel, et al.
Cancer Research|November 20, 2002
Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copperKuniyuki Katano, Akira Kondo, Roohangiz Safaei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cellsRoohangiz Safaei, Kuniyuki Katano, Barrett J Larson, et al.
American Journal of Obstetrics and Gynecology|September 14, 2025
Uterine cancer diagnosis at age 65: onset of Medicare eligibility and impact of Medicaid expansionKevin J Rouse, Ling Chen, Tracy M Layne, et al.
Molecular Cancer|January 8, 2014
ZNF300P1 encodes a lincRNA that regulates cell polarity and is epigenetically silenced in type II epithelial ovarian cancerBrian Gloss, Kim Moran-Jones, Vita Lin, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 24, 2011
TLE3 expression is associated with sensitivity to taxane treatment in ovarian carcinomaGoli Samimi, Brian Z Ring, Doug T Ross, et al.
Gynecologic Oncology|February 4, 2018
Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practicesGoli Samimi, Britton Trabert, Máire A Duggan, et al.
Disease Markers|December 7, 2007
Etiology and pathogenesis of epithelial ovarian cancerSamuel C Mok, Joseph Kwong, William R Welch, et al.
CA: a Cancer Journal for Clinicians|May 30, 2018
Ovarian cancer statistics, 2018Lindsey A Torre, Britton Trabert, Carol E DeSantis, et al.
JNCI Cancer Spectrum|September 13, 2024
Primary care physicians and laypersons' perceptions of multicancer detection clinical trial designsGoli Samimi, Sarah M Temkin, Carol J Weil, et al.
Pageof 8

Showing results (41-50 of 73) with videos related to

Sort By:
Pageof 8
Cancer Chemotherapy and Pharmacology|September 21, 2004
cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistanceGoli Samimi, Gerald Manorek, Rob Castel, et al.
Cancer Research|November 20, 2002
Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copperKuniyuki Katano, Akira Kondo, Roohangiz Safaei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cellsRoohangiz Safaei, Kuniyuki Katano, Barrett J Larson, et al.
American Journal of Obstetrics and Gynecology|September 14, 2025
Uterine cancer diagnosis at age 65: onset of Medicare eligibility and impact of Medicaid expansionKevin J Rouse, Ling Chen, Tracy M Layne, et al.
Molecular Cancer|January 8, 2014
ZNF300P1 encodes a lincRNA that regulates cell polarity and is epigenetically silenced in type II epithelial ovarian cancerBrian Gloss, Kim Moran-Jones, Vita Lin, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 24, 2011
TLE3 expression is associated with sensitivity to taxane treatment in ovarian carcinomaGoli Samimi, Brian Z Ring, Doug T Ross, et al.
Gynecologic Oncology|February 4, 2018
Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practicesGoli Samimi, Britton Trabert, Máire A Duggan, et al.
Disease Markers|December 7, 2007
Etiology and pathogenesis of epithelial ovarian cancerSamuel C Mok, Joseph Kwong, William R Welch, et al.
CA: a Cancer Journal for Clinicians|May 30, 2018
Ovarian cancer statistics, 2018Lindsey A Torre, Britton Trabert, Carol E DeSantis, et al.
JNCI Cancer Spectrum|September 13, 2024
Primary care physicians and laypersons' perceptions of multicancer detection clinical trial designsGoli Samimi, Sarah M Temkin, Carol J Weil, et al.
Pageof 8